Total operating expenses 404,164 276,404 39,445
---------- ----------- -----------
Income (loss) from operations (183,259) 30,858 4,404
Other income (expenses):
Late fees related to social
security insurance (446) (213) (30)
Government grants 14,628 3,864 551
Financial expenses - net (12,968) (6,573) (938)
Fair value changes of warrant
liability 6,851 315 45
Other income (expense) - net (149) (6,454) (921)
Total other income (expense) - net 7,916 (9,061) (1,293)
---------- ----------- -----------
Income (loss) before income taxes (175,343) 21,797 3,111
Income tax benefit (expense) 820 (1,218) (174)
---------- ----------- -----------
Net income (loss) (174,523) 20,579 2,937
---------- ----------- -----------
Net income (loss) attributable to
Lakeshore Group (174,523) 20,579 2,937
========== =========== ===========
Net income (loss) (174,523) 20,579 2,937
Other comprehensive income
(loss): Foreign currency
translation adjustment 3,166 (4,900) (700)
---------- ----------- -----------
Total comprehensive income (loss) (171,357) 15,679 2,237
========== =========== ===========
Earnings (loss) per share:
-- Basic and Diluted (1.88) 0.11 0.02
========== =========== ===========
Weighted average number of
ordinary shares outstanding:
-- Basic and Diluted 93,058,197 190,429,732 190,429,732
========== =========== ===========
Lakeshore Biopharma Co., Ltd
Unaudited Reconciliations of Non-GAAP Results
(All amounts in thousands)
Six Months Ended September 30,
-----------------------------------
2023 2024 2024
------------- ---------- -------
RMB RMB US$
Net income (loss) (174,523) 20,579 2,937
Add: income tax expense (benefit) (820) 1,218 174
Add: financial expenses - net 12,968 6,573 938
Add: depreciation and amortization 23,734 25,414 3,627
------------- ---------- -------
EBITDA (138,641) 53,784 7,676
============= ========== =======
Add: Share-based compensation
expenses - 1,659 237
Add: late fees related to social
security insurance 446 213 30
Add: other income (expense) - net 149 6,454 921
Add: fair value changes of warrant
liability (6,851) (315) (45)
Add: government grants (14,628) (3,864) (551)
------------- ---------- -------
Adjusted EBITDA (159,525) 57,931 8,268
============= ========== =======
Six Months Ended September 30,
-----------------------------------
2023 2024 2024
------------- ---------- -------
RMB RMB US$
Net income (loss) (174,523) 20,579 2,937
Add: share-based compensation
expenses - 1,659 237
Add: loss on disposal of property,
plant and equipment - 8,210 1,172
------------- ---------- -------
Adjusted net income (loss) (174,523) 30,448 4,346
============= ========== =======
View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-reports-unaudited-financial-results-for-the-first-half-of-fiscal-year-2025-and-updates-full-year-guidance-302336215.html
SOURCE LakeShore Biopharma
/CONTACT: Yiyang Wang, ir@lakeshorebio.com
(END) Dow Jones Newswires
December 19, 2024 09:05 ET (14:05 GMT)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。